At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
ACT-774312 +1 moredrug
Likely dose
ACT-774312 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, 12-week Treatment Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis
In Brief
A Phase 2 clinical trial evaluating ACT-774312 and Placebo for Bilateral Nasal Polyposis. Completed, enrolled 10 participants across 2 sites in 2 countries.
Detailed Summary
The study will evaluate the effect of ACT-774312 on the nasal polyps and will assess the safety and tolerability of ACT-774312 in the patients with bilateral nasal polyposis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBilateral Nasal Polyposis
CountriesBelgium, Germany
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartOct 2018
Primary CompletionNov 2020
Study CompletionDec 2020
TodayJul 2026
First PostedSep 28, 2018
Enrollment StartOct 19, 2018
Primary CompletionNov 24, 2020
Study CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.8 years ago
Interventions
ACT-774312drug
ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312
Placebodrug
Matching placebo hard gelatin capsules